CA2480697A1 - Association d'un antithrombotique et d'aspirine - Google Patents

Association d'un antithrombotique et d'aspirine Download PDF

Info

Publication number
CA2480697A1
CA2480697A1 CA002480697A CA2480697A CA2480697A1 CA 2480697 A1 CA2480697 A1 CA 2480697A1 CA 002480697 A CA002480697 A CA 002480697A CA 2480697 A CA2480697 A CA 2480697A CA 2480697 A1 CA2480697 A1 CA 2480697A1
Authority
CA
Canada
Prior art keywords
compound
aspirin
pharmaceutically acceptable
pharmaceutical composition
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002480697A
Other languages
English (en)
French (fr)
Inventor
Tony Verbeuren
Gilbert Lavielle
Bernard Cimetiere
Marie-Odile Vallez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2480697A1 publication Critical patent/CA2480697A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002480697A 2002-04-05 2003-04-04 Association d'un antithrombotique et d'aspirine Abandoned CA2480697A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0204222A FR2838057B1 (fr) 2002-04-05 2002-04-05 Nouvelle association d'un antithrombotique et d'aspirine
FR02/04222 2002-04-05
PCT/FR2003/001054 WO2003084525A1 (fr) 2002-04-05 2003-04-04 Nouvelle association d'un antithrombotique et d'aspirine

Publications (1)

Publication Number Publication Date
CA2480697A1 true CA2480697A1 (fr) 2003-10-16

Family

ID=28052120

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002480697A Abandoned CA2480697A1 (fr) 2002-04-05 2003-04-04 Association d'un antithrombotique et d'aspirine

Country Status (26)

Country Link
US (1) US7618955B2 (https=)
EP (1) EP1496884B1 (https=)
JP (1) JP4065853B2 (https=)
KR (1) KR100645143B1 (https=)
CN (1) CN1297265C (https=)
AR (1) AR039253A1 (https=)
AT (1) ATE329591T1 (https=)
AU (1) AU2003246774B2 (https=)
BR (1) BR0309019A (https=)
CA (1) CA2480697A1 (https=)
CY (1) CY1105106T1 (https=)
DE (1) DE60306133T2 (https=)
DK (1) DK1496884T3 (https=)
EA (1) EA006978B1 (https=)
ES (1) ES2264533T3 (https=)
FR (1) FR2838057B1 (https=)
GE (1) GEP20074101B (https=)
MA (1) MA27114A1 (https=)
MX (1) MXPA04009760A (https=)
NO (1) NO20044700L (https=)
NZ (1) NZ535430A (https=)
PL (1) PL371620A1 (https=)
PT (1) PT1496884E (https=)
UA (1) UA79457C2 (https=)
WO (1) WO2003084525A1 (https=)
ZA (1) ZA200407593B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMP200800012B (it) * 2005-07-22 2008-02-27 Procter & Gamble Composizioni per ridurre l'incidenza di aritmia indotta da farmaco
EP2155195B1 (en) * 2007-04-13 2014-07-16 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
JP2009001537A (ja) * 2007-06-25 2009-01-08 Lab Servier 血管障害の処置を目的とする医薬の入手における抗アテローム血栓化合物の使用
FR2920772B1 (fr) * 2007-09-11 2009-10-23 Servier Lab Association entre un anti-atherothrombotique et un inhibiteur de l'enzyme de conversion de l'angiotensine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711139B1 (fr) * 1993-10-15 1995-12-01 Adir Nouveaux dérivés de 1,2,3,4-tétrahydronaphtalène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
US7618955B2 (en) 2009-11-17
FR2838057A1 (fr) 2003-10-10
FR2838057B1 (fr) 2005-07-08
ES2264533T3 (es) 2007-01-01
UA79457C2 (en) 2007-06-25
HK1076034A1 (en) 2006-01-06
AU2003246774B2 (en) 2007-02-15
PT1496884E (pt) 2006-09-29
JP4065853B2 (ja) 2008-03-26
CN1646111A (zh) 2005-07-27
NZ535430A (en) 2006-09-29
CY1105106T1 (el) 2009-11-04
NO20044700L (no) 2004-10-29
EA200401293A1 (ru) 2005-02-24
EP1496884A1 (fr) 2005-01-19
BR0309019A (pt) 2005-02-01
DE60306133T2 (de) 2007-01-04
ZA200407593B (en) 2006-07-26
WO2003084525A1 (fr) 2003-10-16
ATE329591T1 (de) 2006-07-15
CN1297265C (zh) 2007-01-31
MA27114A1 (fr) 2004-12-20
GEP20074101B (en) 2007-05-10
DK1496884T3 (da) 2006-10-02
JP2005528376A (ja) 2005-09-22
KR20040098053A (ko) 2004-11-18
KR100645143B1 (ko) 2006-11-10
DE60306133D1 (de) 2006-07-27
MXPA04009760A (es) 2004-12-13
US20050143354A1 (en) 2005-06-30
EP1496884B1 (fr) 2006-06-14
PL371620A1 (en) 2005-06-27
AU2003246774A1 (en) 2003-10-20
EA006978B1 (ru) 2006-06-30
AR039253A1 (es) 2005-02-16

Similar Documents

Publication Publication Date Title
JP6505607B2 (ja) 固溶体組成物および心血管疾患における使用
Kono et al. Neurovascular protection by telmisartan via reducing neuroinflammation in stroke-resistant spontaneously hypertensive rat brain after ischemic stroke
EP1656131B1 (fr) Utilisation de la betaine pour le traitement de la claudication intermittente
EP1496884B1 (fr) Association d'un antithrombotique et d'aspirin et son utilisation pour le traitement des maladies thrombotiques atherosclereuses
CA2251226C (fr) Utilisation des derives 2,5-dihydroxybenzenesulfoniques pour la fabrication de medicaments destines a la normalisation de la fonction endotheliale, pour le traitement de la dysfonction sexuelle et des complications vasculaires du diabete, ainsi que des troubles vasculaires d'origine endotheliale
WO1990013290A1 (fr) Composition pharmaceutique a base de paracetamol
EP0029790B1 (fr) Nouveau médicament à base d'aspirine et d'heptaminol
CA2540062A1 (fr) Nouvelle association d'un anti-atherothrombotique et d'un antiagregant plaquettaire
CA3089350A1 (fr) Derives aminoacides contenant un groupement disulfanyle sous forme d'un inhibiteur de nep et d'apn pour la prevention et le traitement des douleurs relatives au nerf trijumeau
WO2014049300A1 (fr) Utilisation topique du laropiprant pour le traitement de la rosacée
FR2833173A1 (fr) Preparation antipyretique renfermant du xylitol
WO2019098984A1 (en) Synergistic combination of diclofenac, famotidine and a carbonate
FR2521997A1 (fr) Nouvelle association medicamenteuse a base de morniflumate
JP2005528376A5 (https=)
EP0635267A1 (fr) Compositions à base d'acides gras douées de propriétés anti-inflammatoires
Lioté et al. Actualité 2013 de la goutte
EP0545759A1 (fr) Utilisation d'un acide aminé soufré, éventuellement en association avec la pyridoxine, pour la préparation d'un médicament destiné au traitement de l'eczéma
HK1076034B (en) Novel association of an antithrombotic agent with aspirin and use thereof for the manufacture of a medicament for treating atherothrombotic diseases
EP1842537A1 (fr) Utilisation d'un compose anti-atherothrombotique pour l'obtention de medicaments destines au traitement des troubles vasculaires
TR201711764A2 (tr) Ağrı ve enflamasyonun tedavisi için diklofenak ve H2 reseptör antagonistleri.
BE894696A (fr) Nouveaux medicaments a base de 9,10-dihydro-ergonine pour le traitement de l'arteriosclerose

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued